We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > enzalutamide

News List

EC approves Xtandi™ for third prostate cancer indication europeanpharmaceuticalreview
May 07, 2021
Xtandi™ (enzalutamide) was approved for metastatic hormone-sensitive prostate cancer after it reduced the risk of radiographic progression or death by 61 percent in a trial.
BDR Pharma launches 80mg of Enzalutamide for prostate cancer treatment expresspharma
September 22, 2020
It reduces the pill burden and expected to increase the patient compliance.
Zydus Cadila launches Enzalutamide to treat prostate cancer expresspharma
May 11, 2020
The therapy priced at nearly two-thirds the cost of the currently available products in the market.
ICR welcomes new advanced prostate cancer treatment guideline pharmatimes
May 08, 2020
The Institute of Cancer Research, London, has welcomed approval of targeted hormone therapies enzalutamide and abiraterone as first-line NHS treatments for men with advanced prostate cancer.
ASCO: Enzalutamide Beneficial in Metastatic Prostate Cancer drugs
June 06, 2019
Enzalutamide Beneficial in Metastatic Prostate Cancer.